Immuno-Oncolytic MVTT Virus Enhances Mesothelioma Treatment
Immuno-Oncolytic Modified Vaccinia Tian Tan Virus and Methods of Treating Cancer
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This technology combines the intratumoral administration of the modified vaccinia Tian Tan (MVTT) virus with the depletion of myeloid-derived suppressor cells (MDSCs) to induce potent antitumor T cell immune responses. It effectively treats mesothelioma and melanoma by restoring cytotoxic CD8+ T cell immunity, addressing the limitations of current immunotherapies. Applications include inducing protective anti-cancer immunity for clinical treatments. Preclinical studies show dose-dependent tumor regression and enhanced therapeutic efficacy in solid tumors. Protected under a US provisional patent, this innovation represents a significant advance in cancer immunotherapy.
IP Type or Form Factor: Patent Pending; Process & Method; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Biotechnology; Vaccines
